Document Detail


Effect of date of drug marketing on disproportionality measures in pharmacovigilance: the example of suicide with SSRIs using data from the UK MHRA.
MedLine Citation:
PMID:  19419238     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Warnings concerning an increased risk of suicide in patients treated with selective serotonin reuptake inhibitors (SSRIs) re-emerged in early 2003, culminating in the broadcast of a television programme in the UK. In the following months, cumulated proportional reporting ratios showed that the most recently marketed drug, escitalopram, had a much higher proportion of reports of suicide to other adverse drug reactions (ADRs) than the other drugs in the class.
OBJECTIVE: To study the reporting patterns over time concerning suicide with the six SSRIs marketed in the UK as of March 2003 and their potential effect on disproportionality signal detection.
METHODS: Monthly cumulated numbers of reports were obtained from the UK Medicines and Healthcare products Regulatory Agency (MHRA), from the time of the first marketing of the drugs concerned and monthly for the 2 months prior to and the 9 months following the broadcast of the television programme (broadcast date: 11 May 2003), and the monthly ratio of suicide to other reports was computed for each SSRI individually and for all SSRIs combined.
RESULTS: Of the six SSRIs studied, five (citalopram, paroxetine, fluoxetine, sertraline and venlafaxine) had been marketed for several years and escitalopram for only a few months. At the end of the analysis period, 1.42% (4/281) of all ADR reports for escitalopram were of suicide versus 0.58% for the other five drugs combined (146/25 197). For all SSRIs combined, suicide represented 0.5% (123/24 315) of reports before the broadcast of the television programme, and increased to 2.3% (27/1163) following the programme. For escitalopram, suicide represented 1.1% (1/89) of all ADR reports before the television programme and 1.6% (3/192) afterwards. For the five other drugs combined, suicide represented 0.5% (122/24 226) of ADR reports before the television programme and 2.5% (24/971) afterwards (varying from 1.4% to 4.7% for the various drugs). The post-programme events represented 68% of all reports and 75% of suicides for escitalopram, whereas for older drugs they represented 3.6% of reports and 13% of suicides.
CONCLUSION: For older drugs, the events reported during the high-reporting post-television programme period were diluted by years of low reporting. For escitalopram, although the television programme had little absolute impact on the number of reports, because the drug had been on the market for such a short period of time, a large relative effect was observed. Differential effects related to time on market on cumulated reporting of adverse drug reactions should be taken into account when analysing spontaneous reporting databases with automated signal generation methods after an alert has changed the spontaneous reporting patterns. Proper use of measures of disproportionality requires thorough knowledge of potential biases and careful analysis of reporting patterns. We found no obvious differences between SSRIs once these were taken into account.
Authors:
Antoine Pariente; Amélie Daveluy; Anne Laribière-Bénard; Ghada Miremont-Salame; Bernard Begaud; Nicholas Moore
Related Documents :
10967148 - Incidence and preventability of adverse drug events in nursing homes.
6507438 - Administrative reports for monitoring pharmacy purchasing.
6430038 - Drug utilization and morbidity statistics for the evaluation of drug safety in sweden.
6464798 - Adverse drug reactions. an epidemiological study at psychiatric hospitals.
16930188 - Us2 drug related oro-facial disease.
19851518 - Treatment of refractory complex partial seizures: role of vigabatrin.
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Drug safety     Volume:  32     ISSN:  0114-5916     ISO Abbreviation:  Drug Saf     Publication Date:  2009  
Date Detail:
Created Date:  2009-05-07     Completed Date:  2009-07-10     Revised Date:  2014-11-17    
Medline Journal Info:
Nlm Unique ID:  9002928     Medline TA:  Drug Saf     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  441-7     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adverse Drug Reaction Reporting Systems*
Algorithms
Citalopram / adverse effects*
Databases, Factual
Great Britain
Humans
Odds Ratio
Product Surveillance, Postmarketing
Serotonin Uptake Inhibitors / adverse effects*
Suicide / statistics & numerical data*
Time Factors
Chemical
Reg. No./Substance:
0/Serotonin Uptake Inhibitors; 0DHU5B8D6V/Citalopram

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Avoidability of adverse drug reactions spontaneously reported to a French regional drug monitoring c...
Next Document:  Visualisation and quantification of morphogen gradient formation in the zebrafish.